SCHEMBL348744

SCHEMBL348744

CC(C)(C)NC(=O)c1ccc(CN2CCN(C(=O)OC(C)(C)C)CC2)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
KDM4E B2RXH2 2/20 0.48
GAA P10253 1/20 0.48
VEGFA P15692 1/20 0.48
EGLN1 Q9GZT9 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 3/20 0.47
LMNA P02545 2/20 0.45
GNRHR P30968 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPK8 P45983 1/20 0.43
HRH3 Q9Y5N1 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
ACKR3 P25106 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346982 0.86 ALDH1A1 (0.74) ALDH1A1NPSR1KDM4EGAAVEGFA
SCHEMBL347202 0.86 ALDH1A1 (0.54) ALDH1A1NPSR1KDM4EGAASMN1; SMN2
SCHEMBL347125 0.84 ALDH1A1 (0.52) ALDH1A1NPSR1KDM4EGAAVEGFA
SCHEMBL1087440 0.81 ALDH1A1 (0.51) ALDH1A1NPSR1VEGFAEGLN1SMN1; SMN2
SCHEMBL346759 0.80 KDM4E (0.53) ALDH1A1NPSR1KDM4EGAASMN1; SMN2
SCHEMBL4659579 0.78 CHRM2 (0.45) ALDH1A1NPSR1KDM4EVEGFAEGLN1
SCHEMBL1022120 0.76 GLS (0.49) ALDH1A1KDM4EGAAVEGFAEGLN1
SCHEMBL31349287 0.76 POLB (0.56) ALDH1A1NPSR1KDM4EVEGFAEGLN1
SCHEMBL348145 0.74 KDM4E (0.43) ALDH1A1NPSR1KDM4EGAASMN1; SMN2
SCHEMBL4938599 0.74 VEGFA (0.56) ALDH1A1NPSR1VEGFAEGLN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 EP disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES NPC1, ABCB11, NPC1L1 ALDH1A1 1156/4885NPSR1 712/4885KDM4E 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.